» Download Public Reports
68 reports
- Company report
- May 2012
- 4 pages
... And helping to shorten their discovery times. Complete genomics Services provide customers with further insights into the genetic underpinnings of human diseases, including complex diseases such as cancer ...
May 2012
... And production of monoclonal antibodies and antibody-based protein drugs. We carry out environmental management activities that meet the company S mid- to long-term strategies and the policies of its ...
April 2012
... Is a human keratinocyte line that rele- ases abnormal level of chemokines, including tarc, mdc, rantes, vascular endothelial growth factor, and eotaxin when stimulated with tnf- And ifn- . When released from ...
April 2012
... To believe food biotechnology might bring benefits in the next five years. Because of consumer misgivings towards gm crops particularly in high-income importing countries like japan and republic of korea ...
May 2012
... This provisional pdf corresponds to the article as it appeared upon acceptance. Fully formatted pdf and full text (html) versions will be made available soon. biosimilars; a unique opportunity ...
May 2012
... Oxidase or ethylene-insensitive3 as well as in transgenic plants impaired in ros production. All tested transgenic plants were more tolerant against p. Parasitica var nicotianae infection as determined based on trypan ...
September 2012
... Sweetpotato plants on marginal lands (kribb) genome transcriptome proteome metabolome what can happen What appears to be happening What makes it happen What actually happens Phenotype ...
April 2013
... Innovation in biologics will be the theme of this meeting. Among the biologic drug cands, monoclonal antibody (mab) is the fastest growing area of global pharmaceutical market. Mab is set to lead ...
May 2012
... A major technical challenge in the cost-effective production of cellulosic biofuel is the need to lower the cost of plant cell wall degrading enzymes (pcde), which is required for the production of sugars ...
» Purchase Premium Reports
(From $ 250 - $ 6 125)
34 reports
- $ 6 860
- Industry report
- May 2013
- by France Innovation Scientifique et Transfert
Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged ...
May 2013
$ 4 060
Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged ...
May 2013
$ 2 064
Product Description The new Competitive Intelligence Report Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis of the product portfolios and development ...
April 2013
$ 516
Product description The present Competitive Intelligence Report about G-CSF and GM-CSF product portfolios and R&D pipelines provides a competitor evaluation in the field of G-CSF & GM-CSF branded products ...
March 2013
$ 300
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...
March 2013
$ 300
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...
March 2013
$ 250
Summary CHA Bio & Diostech Co., Ltd. (CHA Bio & Diostech) is a bio technology company, based in South Korea. It develops advance biomedicine through applied life science and technology. The company's products ...
